-
After price correction, more than 300 drug regulations in the province were withdrawn from the Internet
Time of Update: 2022-03-07
In 2020, Liaoning Province also requires that the unselected drugs included in the scope of centralized drug procurement organized by the state implement a linked gradient price reduction .
-
The influx of innovative pharmaceutical companies has intensified, how to break the situation?
Time of Update: 2022-03-07
According to incomplete statistics, as of February 8, 2022, a total of 243 medical companies in the A-share market have released their 2021 performance forecasts, most of which are expected to increase, but there are also 60 companies that are pre-loss, accounting for about 25% .
-
In 2022, new changes are emerging in the financing of innovative pharmaceutical companies
Time of Update: 2022-03-07
Recently, many pharmaceutical companies have announced the completion of financing, which will be used for the research and development and promotion of new drugs .
-
The environmental protection pressure of the pharmaceutical industry has intensified, and pharmaceutical companies need a diversified approach to energy conservation and emission reduction
Time of Update: 2022-03-07
It is worth mentioning that from the fourth quarter of 2020, with the improvement of national pollution control standards, Northeast Pharmaceuticals has invested another 340 million yuan on the basis of current environmental protection to carry out environmental protection improvements covering waste gas, wastewater and comprehensive utilization.
-
Helping pharmaceutical companies to accelerate innovation, pharmaceutical machine companies will play a big role
Time of Update: 2022-03-07
Affected by this, the domestic pharmaceutical equipment industry will also better help the innovation and development of the pharmaceutical industry, and escort the quality and efficiency of its R&D and production .
-
The performance of multinational pharmaceutical companies has generally recovered, and executives may usher in salary increases!
Time of Update: 2022-03-07
In addition to Roche and Novartis, Bristol-Myers Squibb, Sanofi, Merck, Eli Lilly and other multinational pharmaceutical companies have also achieved performance growth in 2021.
Although these pharmaceutical companies have not yet disclosed executive compensation Look, the total compensation of the CEOs of Johnson & Johnson, AbbVie, and Eli Lilly has exceeded 20 million US dollars .
-
"Integration of Taoism and Devices" Helps China Biopharmaceuticals
Time of Update: 2022-03-07
There are literature data showing that increasing the single-pot culture volume to 15KL can reduce the unit production cost of antibody to about 40USD/g .
So what are the difficulties in designing and manufacturing large-scale bioreactors for cell culture?The answer is "process suitability", not tanks, piping, instrumentation, valves and control systems .
-
6 multinational pharmaceutical companies announced their performance in China, which one performed better?
Time of Update: 2022-03-07
According to incomplete statistics, as of now, six multinational pharmaceutical companies including Roche, Novartis, Merck, Sanofi, AstraZeneca, and Eli Lilly have disclosed their performance in China while disclosing their 2021 financial reports .
-
Cefuroxime Sodium for Injection passed the consistency evaluation of generic drugs
Time of Update: 2022-03-07
(hereinafter referred to as the "Company"), received the "Supplementary Drug Application for Cefuroxime Sodium for Injection" approved and issued by the State Drug Administration.
Cefuroxime Sodium for Injection is Yifan Yosemite Pharmaceutical Technology Co.
jointly invested and established by the company's two wholly-owned subsidiaries, Zhejiang Jutai Pharmaceutical Co.
-
The research and development of PD-(L)1 is becoming more and more popular, and pharmaceutical companies need to be cautious when entering the bureau
Time of Update: 2022-03-07
_ It is worth noting that the industry believes that while more and more PD-(L)1 products are brought to the market to bring more new treatment options to the majority of patients, the competition in this track will become more intense, and product price reductions will enter the "normal" category.
-
Ascletis Pharma Announces Submission of Marketing Authorization Applications for Ritonavir in Multiple European Countries
Time of Update: 2022-03-07
Other marketing authorization applications for ritonavir in European countries, North American countries and Asia-Pacific countries are also expected to be submitted in the near future .
-
Yinming Bio's new CAR-T product announces clinical data, HKP1 inhibitor is approved for clinical use
Time of Update: 2022-03-07
references:[1] Two new breakthroughs have been achieved in the research and development of HPK1 targets of Yinming Bio: the clinical data of cell therapy was announced at the EHA CAR-T conference, and the small molecule drug was approved for clinical use in China.
-
New drug research and development is hot, focusing on these three directions!
Time of Update: 2022-03-07
In recent years, the research and development of ADC drugs has been hot, and the market scale has continued to expand.
In recent years, with the rapid increase in the research and development of new macromolecular drugs in China, the double-antibody track has attracted a number of companies to deploy.
-
Kexing Pharmaceutical's Human Erythropoietin Injection was awarded the "Approval Notice for Supplementary Drug Application"
Time of Update: 2022-03-07
On February 14, Kexing Pharmaceuticals announced that it received the “Approval Notice for Supplementary Drug Application” approved and issued by the State Food and Drug Administration on February 12.
-
Focusing on the research and development of innovative drugs, domestic pharmaceutical companies will continue to set off a "financing wave"
Time of Update: 2022-03-07
This round of financing will be mainly used to further improve Yosano Bio's unique "ready-to-use" CAR-T The cell technology platform CBT-X20 is preparing for the Sino-US New Drug Clinical Trial (IND) application of the core product AT19 and the construction of the company's scientific research and production facilities .
-
In 2022, personnel adjustments in the pharmaceutical industry will still be frequent
Time of Update: 2022-03-07
Qian Guoshuang applied for his resignation as an independent director and member of the nomination committee of the ninth board of directors of the company due to personal reasons.
Chen Yong resigned from the above-mentioned positions, he still served as the deputy general manager of the company .
-
The policy of Chinese herbal medicines in one place is relaxed, and pharmacies can be exempted from fines of 100,000 yuan
Time of Update: 2022-03-06
The policy of Chinese herbal decoction pieces is relaxed, and pharmacies can be exempted from fines of 100,000 A few days ago, the Jiangsu Food and Drug Administration issued the "Guiding Opinions on the Determination of Jiangsu Province Traditional Chinese Medicine Pieces Do Not Comply with Drug Standards and Does Not Affect Safety and Effectiveness (Trial)" (hereinafter referred to as "Opinions") .
-
The growth rate of the centrifuge market exceeds 23%, and the biomedical industry is a major "support force" behind it
Time of Update: 2022-03-06
Some medical centrifuge manufacturers said that facing the future, the company will continue to increase investment in research and development, attach importance to innovation, continuously improve the stability and quality of domestic centrifuges, seize the opportunity of import substitution, and help the pharmaceutical and other industries to develop with higher quality .
-
As long as it is domestically produced, the results of the 21 million device purchase order will be announced (with a list attached)
Time of Update: 2022-03-06
According to information disclosed by Lingang, the initial investment of the Medtronic Lingang project is about 300 million yuan, which will be used for the research and development and industrialization of cardiovascular disease-related products .
-
Centralized procurement attacks pharmaceutical companies in all directions to survive in this way
Time of Update: 2022-03-06
Of course, the hospital can also do both Those who are not guilty, kick them all out, and then enter one back through channels such as the Pharmacy Council;For question 3, in the case of multiple companies being selected, after completing the agreed purchase volume, some provinces may differentiate the preferred products based on price, quality level, A and B categories, etc.
